Now Recruiting for Light-for-PD Clinical Trial!
Watch Jimmy Choi, 5-time American Ninja Warrior and person with PD, talk about the benefits of the Light-for-PD clinical trial.
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.
Trusted by the Fox Trial Finder
Now Recruiting for LightforPd Clinical Trial!
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.
Watch Jimmy Choi, 5-time American Ninja Warrior and person with PD, talk about the benefits of the Light-for-PD clinical trial.
Trusted by the Fox Trial Finder
ADDRESSING MAJOR UNMET NEEDS
A Breakthrough Therapy for People Living with Parkinson’s Disease
Specialized phototherapy addresses both motor and non-motor symptoms
Over 11 million people worldwide live with Parkinson’s disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson’s disease in decades.
Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson’s disease in decades. We have seen large improvements in our proof-of-concept studies – especially in addressing major unmet needs in Parkinson’s. We are initiating a pivotal trial of our key product, Celeste® specialized phototherapy, to confirm safety and sustained efficacy.
Despite the efficacy of dopaminergic drugs, people with PD continue to experience difficulties with unresolved motor symptoms and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function significantly reduces quality of life for many, often preventing those living with PD from working, exercising, socializing, and doing the things they want to do.
We invite you to join us to improve the lives of individuals suffering from neurodegenerative diseases.
Seeing Specialized Phototherapy Clearly
Our non-invasive specialized phototherapy is well on its way to becoming a physician-prescribed standard of care.
When it comes to motor and non-motor symptoms of Parkinson’s, here’s what we’re seeing so far.
PROMISING RESULTS
and enjoyed improved quality of life.
NON-INVASIVE
LIFESTYLE FRIENDLY PROTOCOL
Trending Topics
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care PhotoPharmics, a clinical-stage medtech device company specializing in non-invasive photo neurostimulation, today announced its participation in the 2025...
Understanding and Managing Depression and Anxiety in Parkinson’s
Introduction Did you know that at least 50% of people with Parkinson's Disease (PD) will experience some form of depression during their illness, and up to 40% will face a significant anxiety disorder? If you've been grappling with your mood, you are far from alone....
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, announced the formation of its Commercial Advisory Board (CAB),...
Why Am I So Exhausted? Is Fatigue Related to Parkinson’s?
Introduction If you're living with Parkinson's disease (PD), you might have a deeply personal understanding of what fatigue truly means. It’s a feeling that goes far beyond the simple tiredness you might experience after a long day. Many describe it in profound...
PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies
New clinical sites open in Illinois, Florida, and Arizona; trial remains open to participants across 19 states. PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, announced today that it is expanding study access to states that have...